1,422 results on '"Schwartzberg, Lee"'
Search Results
102. Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—CME information
103. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast Cancer
104. Molecular Characterization of ESR1 Variants in Breast Cancer
105. Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
106. Social Disparities of Pain and Pain Intensity Among Women Diagnosed With Early Stage Breast Cancer
107. Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
108. Pharmacoeconomics of Granulocyte Colony-Stimulating Factor: A Critical Review
109. Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin’s lymphoma receiving CHOP-based chemotherapy
110. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
111. Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden
112. Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
113. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)
114. Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trial.
115. Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
116. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer
117. Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial
118. Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
119. Biomarker testing patterns and actionability in advanced non-small cell lung cancer (aNSCLC) at OneOncology (OneOnc).
120. Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer
121. NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT).
122. Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer
123. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
124. Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
125. A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC)
126. Second- and Third-line Treatment of Patients With Non–Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden
127. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer
128. A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer
129. Impact of Molecular Tumor Board (MTB) on precision oncology in a community setting
130. Comparison of Chemotherapy vs Chemotherapy Plus Total Hysterectomy for Women With Uterine Cancer With Distant Organ Metastasis
131. A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer
132. Phase I/II Study of Ixabepilone plus Capecitabine in Anthracycline–Pretreated/Resistant and Taxane-Resistant Metastatic Breast Cancer
133. Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting
134. Clinical impact of eribulin in the treatment of breast cancer
135. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
136. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer
137. A retrospective study of quality of life in a community sample of patients with early stage breast cancer
138. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study
139. Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer Before Starting Chemotherapy
140. Characterizing unplanned resource utilization associated with cancer-related diarrhea.
141. Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.
142. Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.
143. Estimates of stage-specific preclinical sojourn time across 21 cancer types.
144. Healthcare utilization and costs associated with cancer-related diarrhea.
145. The impact of cancer-related diarrhea on changes in cancer therapy patterns.
146. Perspectives on under-representation of minority patients (pts) in clinical trials.
147. Differences by race in patient-reported symptoms during chemotherapy among women with early-stage, hormone receptor-positive breast cancer.
148. Impact of clinical trial enrollment on episode costs in the Oncology Care Model (OCM).
149. A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC).
150. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.